Auransa
Palo Alto
About Auransa
Auransa is a clinical stage drug development company who aims to invent high value, novel drugs for hard-to-treat diseases like cancer, auto-immune and neurological disorders using its proprietary AI platform and drug discovery expertise. The company's platform is used to understand biology of diseases at subtype level resolution, enabling it to predict compounds and targets of novel pharmacology for responder patient population. Current internal drug pipeline includes a first-in-class investigational new drug for cancer in clinical trials. Auransa has partnership with companies and institutions in the biopharma industry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2020)
- Website: auransa.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/auransa-19141 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.